CD74 Antibodies Rapid Internalization Tumor Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic methods for treating cancer and other diseases using CD74-specific antibodies and antibody-drug conjugates (ADCs) are not sufficiently effective due to limitations in specificity and efficiency, particularly in targeting and internalizing CD74-expressing cells.
Innovation Solution
Development of novel monoclonal CD74-specific antibodies and ADCs with specific VH and VL sequences that exhibit rapid internalization upon binding to CD74, characterized by high affinity and selectivity, enabling efficient killing of CD74-expressing tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional CD74-specific antibodies are used, then they can bind to CD74 antigen, but they exhibit slow internalization and low efficacy in killing tumor cells
Solution Approach 1:
The patent applies parameter changes by modifying the antibody structure to alter its binding characteristics. Specifically, the novel CD74-specific antibodies have modified variable regions that change the binding kinetics and affinity, resulting in rapid internalization upon binding to CD74. This structural parameter modification directly addresses the contradiction by transforming slow internalization into rapid internalization while maintaining or enhancing tumor cell killing efficacy.
2Reliability
If CD74-targeting therapy is applied, then treatment of CD74-positive tumors is achieved, but the low surface expression of CD74 limits therapeutic effectiveness
Solution Approach 1:
The patent applies preliminary action by designing antibodies that induce rapid internalization of CD74 upon binding. This creates a feedback mechanism where the antibody binding triggers increased CD74 internalization and recycling to the cell surface, effectively amplifying the target availability. The preliminary binding event initiates a cascade that overcomes the limitation of low initial surface expression, thereby improving therapeutic reliability despite low baseline CD74 levels.
Solution Approach 2:
The patent utilizes feedback mechanisms where the initial antibody binding to CD74 triggers cellular internalization processes. This internalization event creates a feedback loop that regulates further CD74 expression and trafficking to the cell surface, effectively amplifying the target availability. The feedback mechanism transforms the limitation of low surface expression into an advantage by dynamically increasing target engagement through antibody-induced internalization and recycling.
3Productivity
If existing ADC formats are used, then they provide some therapeutic benefit, but they lack sufficient specificity and efficiency in targeting CD74-expressing cells
Solution Approach 1:
The patent applies segmentation by dividing the antibody into distinct functional modules with optimized properties. The variable regions are engineered for high-affinity, specific binding to CD74, while the constant regions are configured to optimize ADC functionality and cellular uptake. This modular segmentation allows independent optimization of specificity and killing efficiency, resolving the contradiction between these two parameters.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel antibodies and ADCs demonstrate enhanced specificity and efficacy in inducing cell death in CD74-expressing tumor cells, including in vivo models, despite low surface expression of CD74 on tumor cells, and show promise in both therapeutic and prophylactic treatments.
Implementation Method 1
the antibodies are characterized by rapid internalization upon binding to CD74 antigen
Implementation Method 2
The novel ADCs are characterized by a high efficiency in killing CD74-expressing tumor cells
Data Source
Figure 1a~1f
Figure 2a~2b
Figure 3a~3b
AI summary
Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.